Peroxisome proliferator-activated receptor γ regulates angiotensin II-induced catalase downregulation in adventitial fibroblasts of rats  by Yang, Weiwei et al.
FEBS Letters 585 (2011) 761–766journal homepage: www.FEBSLetters .orgPeroxisome proliferator-activated receptor c regulates angiotensin II-induced
catalase downregulation in adventitial ﬁbroblasts of rats
Weiwei Yang a,1, Jia Zhang a,1, Haiya Wang a, Weili Shen b, Pingjin Gao b, Manpreet Singh c, Ningyuan Fang a,⇑
aDivision of Geriatrics, RenJi Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
b Joint Laboratory of Vascular Biology of Health Science Center and Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,
and Shanghai Institutes of Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai 200025, China
cDepartment of Pathology, University of Western Ontario, London, Ontario, Canadaa r t i c l e i n f o
Article history:
Received 10 January 2011
Accepted 27 January 2011
Available online 3 February 2011
Edited by Laszlo Nagy
Keywords:
Adventitial ﬁbroblast
Angiotensin II
Catalase
Peroxisome proliferator-activated receptor c0014-5793/$36.00  2011 Federation of European Bio
doi:10.1016/j.febslet.2011.01.040
Abbreviations: AFs, adventitial ﬁbroblasts; Ang II,
type 1 receptor; CAT, catalase; ERK1/2, extracellular
H2O2, hydrogen peroxide; PPAR c, peroxisome proli
ROS, reactive oxygen species; 15d-PGJ2, 15-deoxy-D1⇑ Corresponding author. Address: Division of Geriat
Jiao Tong University School of Medicine, No. 145. Shan
200001, China. Fax: +86 21 58893771.
E-mail address: rjfangny@shsmu.edu.cn (N. Fang).
1 These two authors equally contributed to this wora b s t r a c t
Peroxisome proliferator-activated receptor (PPAR) c ligands oppose the effect induced by angioten-
sin II (Ang II) to reduce oxidative stress and improve antioxidant status. In this study, Ang II inhib-
ited catalase (CAT) and peroxisome proliferator-activated receptor c (PPAR c) protein and mRNA
expressions. Transfection with PPAR c small-interfering RNA (siRNA) led to a reduction in CAT
expression. PPAR c ligands enhanced CAT expression and inhibited extracellular signal-regulated
kinase 1/2 activation. We further reveal that Ang II type 1 receptor is not involved in the inhibitory
effects of PPAR c ligands on Ang II stimulatory events.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction activity in Ang II-incubated AFs and the potential role of PPAR c inPeroxisome proliferator-activated receptor (PPAR) c is a ligand-
activated transcription factor that controls the expressions of a
large array of genes by binding to PPAR response element (PPRE)
in their promoter regions [1,2]. Increasing evidence suggests that
peroxisome proliferator-activated receptor c (PPAR c) plays a cru-
cial role in metabolism, cellular differentiation and vascular
inﬂammation [3,4]. Recently, abundant PPAR c mRNA expression
has been observed in the aorta in adventitial ﬁbroblasts (AFs), with
reactive oxygen species (ROS) production reduced by PPAR c
ligands 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) and pioglitaz-
one [2]. Although it has been demonstrated that angiotensin II
(Ang II) inhibits PPAR c transcriptional activity in vascular smooth
muscle cells (VSMCs) [5], and that PPAR c ligands exert antioxidant
action on the cardiovascular system by antagonizing Ang II effects
[6], little information is available regarding PPAR c expression andchemical Societies. Published by E
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signal-regulated kinase 1/2;
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k.the regulation of antioxidant enzymes stimulated by Ang II.
Catalase (CAT) is one of the major antioxidant enzymes catalyz-
ing dismutation of hydrogen peroxide (H2O2) into water and
molecular oxygen, protecting cells from damage of oxidative stress
[7]. CAT deﬁciency can lead to accumulation of H2O2, which is not
only toxic to cells but can also be a precursor of other toxic species.
Therefore, assessment of CAT expression is critical for discerning
the underlying mechanism of pathological vascular structural
changes. There have been contradictory reports regarding the reg-
ulation of CAT expression in different cell types and tissues, with
its activity and/or levels decrease, increase, or unchanged [8–10].
Moreover, upstream signaling events, which control the regulation
of CAT, remain largely unknown.
Keeping in mind these facts, we try to unravel the effect of
Ang II on CAT and PPAR c expressions in AFs of rats, especially
the regulation of PPAR c on CAT gene expression induced by Ang
II.2. Materials and methods
2.1. Materials
Ang II, 15d-PGJ2, pioglitazone, GW9662, losartan and PD98059
were purchased from Sigma (St. Louis, MO, USA). Actinomycin D
and cycloheximide were from Beyotime Institute of Biotechnologylsevier B.V. All rights reserved.
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Chemical (Ann Arbor, MI, USA). Antibodies to PPAR c and Ang II
type 1 receptor (AT1R) were obtained from Santa Cruz (Santa Cruz,
CA, USA).
2.2. Cell culture
All animal procedures followed the Guide for the Care and Use
of Laboratory Animals (National Institutes of Health. USA). AFs
were isolated from thoracic aortas of male Sprague–Dawley rats
as described previously [11]. Cells were grown in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 20% fetal bovine
serum, 100 U/ml penicillin and 100 lg/ml streptomycin in 5% CO2
at 37 C. Fibroblasts were used between passages 3 and 6 for all
experiments. The subconﬂuent cells were made quiescent by incu-
bation in serum-free medium for an additional 24 h before
stimulation.
2.3. Western blot analysis
Following stimulation, total protein was extracted and protein
concentration was measured with Protein Extraction Kit and BCA
Protein Assay Kit respectively (Beyotime, China). Protein samples
were separated on 10% SDS–PAGE gels and transferred onto nitro-
cellulose membranes. After blocking with 5% non-fat milk in Tris-
buffered saline Tween, the membranes were incubated with pri-
mary antibodies at 4 C overnight. After washing, the membranes
were incubated with horseradish peroxidase-conjugated antibody
for 1 h at room temperature. Western blots were developed using
ECL (Roche, Mannheim, Germany) and quantiﬁed by scanning
densitometry.Fig. 1. Effect of Ang II on protein and mRNA expressions of CAT and PPAR c in AFs. Cells
expressions of CAT (A and B) and PPAR c (C and D) were analyzed by Western blot and R2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated with TRIzol (Invitrogen, USA) and re-
verse transcription-polymerase chain reaction was performed as
described previously [12]. The primers used were as follows:
CAT, 50-GAG TCT CTC CAT CAG GTT AC-30 (sense) and 50-TGA TGC
CCT GGT CAG TCT TG-30 (antisense); PPAR c, 50-TGG ACC TCT
CTG TGA TGG ATG -30 (sense) and 50-GGC CTG TTG TAG AGT TGG
GTT -30 (antisense). The temperature programme for the ampliﬁca-
tion was 32 cycles of 50 s at 94 C, 45 s at 60 C and 50 s at 72 C.
2.5. Small-interfering RNA (siRNA) transfection
The siRNA targeting PPAR c (sense: 50-CCU CCC UGA UGA AUA
AAG ATT-30, antisense: 50-UCU UUA UUC AUC AGG GAG GTT-30),
AT1R (sense: 50-CGU CAU CCA UGA CUG UAA ATT-30, antisense:
50-UUU ACA GUC AUG GAU GAC GTT-30) and negative control siR-
NA (NC siRNA) (sense: 50-UUC UCC GAA CGU GUC ACG UTT-30,
antisense: 50-ACG UGA CAC UGG CGG AGA ATT-30) were synthe-
sized by GenePharma (Shanghai, China). For transfection, cells
were plated onto six-well plates and grown to >80% conﬂuence.
100 nM siRNA was then delivered to cells for 24 h using FuGENE
HD Transfection Reagent (Mannheim, Germany) according to the
manufacturer’s instruction.
2.6. Statistical analysis
All values are expressed as mean ± S.D. Statistical signiﬁcance
was determined using one-way ANOVA followed by a post hoc test.
A value of P < 0.05 was considered to be statistically signiﬁcant.were stimulated with Ang II (0.1 lM) for 0, 0.5, 2, 6, 12, 24 h. The protein and mRNA
T-PCR. Data are means ± S.D. from three independent experiments. ⁄⁄P < 0.01 vs. 0 h.
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3.1. Effect of Ang II on protein and mRNA expressions of CAT and PPAR
c in AFs
AFs were cultured with medium in the presence of 0.1 lM Ang
II for 0–24 h (0, 0.5, 2, 6, 12, and 24 h). Data in Fig. 1A and B showed
that Ang II decreased the protein andmRNA expressions of CAT in aFig. 2. PPAR c ligands inhibited Ang II-induced CAT downregulation in AFs. Cells were p
PGJ2 and pioglitazone (10 lM each) for 30 min, and subsequently stimulated with Ang
western blot and RT-PCR. (D) After preincubation with 15d-PGJ2 and pioglitazone (10 l
stained with actinomycin D (5 lg/ml) for 0, 4, and 8 h. (E) After preincubation with/with
pioglitazone (10 lM each) for another 30 min, and then stained with Ang II (0.1 lM) f
control, ##P < 0.01 vs. Ang II, $$P < 0.01 vs. Ang II + 15d-PGJ2, $$P < 0.01 vs. Ang II + pioglitime-dependent manner after a transient increase. Similar results
were found for PPAR c protein and mRNA levels (Fig. 1C and D).
3.2. PPAR c ligands inhibited Ang II-induced CAT downregulation
in AFs
Under suggestion of the above-mentioned results, we evaluated
effects of PPAR c ligands on Ang II-induced CAT expression. Asreincubated with/without GW9662 (50 lM) for 30 min before the addition of 15d-
II (0.1 lM) for 24 h.CAT protein (A and C) and mRNA (B) levels were measured by
M each) for 30 min, cells were stimulated with Ang II (0.1 lM) for 24 h, and then
out cycloheximide (10 lg/ml) for 30 min, cells were stimulated with 15d-PGJ2 and
or 24 h. Data are means ± S.D. from three independent experiments. ⁄⁄P < 0.01 vs.
tazone.
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protein and mRNA levels of CAT in both Ang II-stimulated AFs
and controls (P < 0.01). Preincubation with PPAR c antagonist
GW9662 blocked the effects of 15d-PGJ2 and pioglitazone
(P < 0.01 vs control) (Fig. 2C).
Then, we examined whether de novo RNA or protein synthesis
was required for CAT mRNA increase by PPAR c lignads in Ang II-
stimulated AFs. Linear regression analysis of CAT turnover in acti-
nomycin D-stimulated cells showed only a slight increase in the
half life of CAT mRNA by PPAR c ligands in Ang II-treated cells
(t1/2 = 6.8 h) versus control (t1/2 = 4.3 h) (Fig. 2D). Preincubation
with the protein synthesis inhibitor cycloheximide increased CAT
mRNA levels in controls and PPAR c ligands plus Ang II-treated
cells (Fig. 2E). These results indicated that PPAR c ligands-induced
upregulation of CAT mRNA was mainly due to enhanced gene
transcription.
3.3. Transcriptional regulation of CAT expression by PPAR c
To establish whether PPAR c is causally involved in the tran-
scriptional regulation of the CAT gene, cells were transiently trans-
fected with siRNA targeted to PPAR c. As seen in Fig. 3, Lack of
PPAR c decreased protein and mRNA levels of PPAR c and CAT
compared with NC siRNA and untreated controls (P < 0.01), thereby
indicating that PPAR c controls the transcription of CAT.Fig. 3. Effect of PPAR c siRNA on CAT expression in AFs. After application of NC siRNA or P
and C) levels were detected by western blot and RT-PCR. Data are means ± S.D. from th3.4. Inhibitory effects of PPAR c ligands on Ang II-mediated CAT
downregulation in AFs by blockade of extracellular signal-regulated
kinase ½ (ERK1/2) and independent of AT1R
As shown in Fig. 4A and B, AT1R antagonist, losartan, and ERK1/
2 antagonist, PD098059, blocked Ang II-induced decrease in CAT
expression in AFs. 15d-PGJ2 and pioglitazone did not have any
additional effects on AT1R blockade, but produced an additional ef-
fect on PD098059 blockade. The AT1R siRNA was then applied to
AFs to further conﬁrm the role of this receptor in the inhibitory ef-
fects of PPAR c lignads. The knockdown efﬁciency of AT1R was 45%,
as determined by western blot (Fig. 4C). Lack of AT1R increased
Ang II-induced CAT production compared with negative control.
However, AT1R siRNA did not change the inhibitory effects of
15d-PGJ2 and pioglitazone on Ang II-induced CAT downregulation
(Fig. 4D). These results suggest that the increase of CAT expression
by PPAR c ligands is not dependent on the existence of AT1R, but
mainly involves blockade of ERK1/2.
4. Discussion
PPAR c has been shown to be expressed in numerous tissues,
where it exerts multiple effects, including regulation of oxidative
stress via transrepression of proinﬂammatory transcription factorsPAR c siRNA (100 nM each) for 24 h, PPAR cmRNA (A) and CAT protein and mRNA (B
ree independent experiments. ⁄⁄P < 0.01 vs. control.
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generation through coordinated transcriptional control of a set of
proteins and enzymes involved in ROS metabolism [13], the
involvement of PPAR c in antioxidant defense has not been inves-
tigated in AFs. Our study demonstrated that normal AFs expressed
PPAR c, which could be decreased by Ang II time dependently after
an adaptive rise. PPAR c ligands 15d-PGJ2 and pioglitazone in-
creased the expression of PPAR c in response to Ang II. These re-
sults indicate that PPAR c ligands may be involved in the effect
of Ang II in AFs through a functional PPAR c pathway.
CAT is an enzyme that is speciﬁcally responsible for cellular
antioxidant defense by catalyzing the decomposition of extracellu-
lar and intracellular H2O2. Studies have described adaptive eleva-
tion of activity and expression of this enzyme after exposure to
stress [15,16]. Moreover, a functional PPRE has been identiﬁed in
the rat microvascular endothelial cells CAT 5’-ﬂanking region
[17]. Hence, we investigated the regulation of PPAR c on Ang II-in-
duced CAT expression in AFs. We found that Ang II time-depen-Fig. 4. Inhibitory effects of PPAR c ligands on Ang II-induced CAT downregulation in A
without losartan (10 lM) and PD98059 (10 lM) or transfected with NC siRNA and AT1R
each) for 30 min, and then stimulated with Ang II (0.1 lM) for 24 h. CAT (A, B and D) and
three independent experiments. ⁄⁄P < 0.01 vs. control, ##P < 0.01 vs. Ang II, #P < 0.05, ##Pdently decreased CAT expression after a transient increase, which
may be a natural response of the cell to cope with oxidative stress.
Since CAT expression is parallel to that of PPAR c in Ang II-stimu-
lated AFs, it is not surprising to speculate that PPAR c may partic-
ipate in the regulation of CAT. Indeed, inhibition of PPAR c
transcription with siRNA led to a reduction in CAT protein and
mRNA expressions in AFs, indicating that PPAR c at least in part
regulates CAT. Speciﬁc activation of PPAR c by 15d-PGJ2 and piog-
litazone remarkably increased CAT protein and mRNA levels in
control ﬁbroblasts and suppressed the decrease of CAT in response
to Ang II. Meanwhile, results with the PPAR c inhibitor GW9662,
which binds to a lysine residue in the ligand binding pocket, per-
manently inhibiting the binding of other ligands [18], demon-
strated that upregulation of CAT by 15d-PGJ2 and pioglitazone
was mediated by PPAR c activation. In addition, increase in CAT
mRNA levels by PPAR c ligands was not associated with changes
in the stability of CAT mRNA. The upregulation of CAT is linked
to an upregulation of its mRNA levels, thereby indicating that theFs by blockade of ERK1/2 and independent of AT1R. Cells were preincubated with/
siRNA (100 nM each) for 24 h before exposure to 15d-PGJ2 and pioglitazone (10 lM
AT1R (C) protein levels were analyzed by Western blot. Data are means ± S.D. from
< 0.01 vs. Ang II + PD98059, $$P < 0.01 vs. Ang II + AT1R siRNA.
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lated AFs result from an altered gene expression rather than from
alterations in post-transcriptional regulation.
Thus, our data imply a potential role of PPAR c in the transcrip-
tional regulation of the CAT gene in AFs. Ang II-induced reduction
of CAT was accompanied by a downregulation of PPAR c expres-
sion and activation. Moreover, the synthetic PPAR c ligand pioglit-
azone and the endogenous ligand 15d-PGJ2 had parallel effects on
CAT expression induced by Ang II.
Although PPAR c ligands classically activate PPAR c to mediate
gene transcription, it has also been shown that these agents can ex-
ert PPAR c-independent cell signaling processes [19]. In fact, PPAR
c ligands may produce beneﬁcial effects by suppressing AT1R
expression in VSMCs [20,21]. However, inhibitory effect of rosiglit-
azone on Ang II-induced TLR4 expression in VSMCs was indepen-
dent of AT1R [4]. Consistent with this report, our ﬁndings
demonstrated that Ang II decreased CAT expression through
AT1R, whereas the inhibitory effects of 15d-PGJ2 and pioglitazone
on Ang II stimulatory events were independent of AT1R. Therefore,
some other mechanisms may also be involved.
As ERK1/2 is implicated in cardiovascular diseases, and is acti-
vated by stimuli such as Ang II [22], it may be possible that
ERK1/2 participates in Ang II-mediated gene expression in AFs.
Our study conﬁrmed this possibility, as indicated by an increase
of CAT expression in the presence of ERK1/2 inhibitor in Ang II-
stimulated cells. Thus, the increase of CAT by PPAR c ligands ob-
served in our study is, at least in part, mediated through the
ERK1/2 signaling pathway.
Taken together, the present study delivers important insights to
the mechanisms of Ang II action in vascular AFs linking PPAR c and
inadequate antioxidant CAT defense. Our results revealed that
PPAR c plays an important role in the downregulation of CAT in-
duced by Ang II. ERK1/2 signaling pathway may contribute to the
suppressive effects of the PPAR c ligands on Ang II-decreased
CAT expression. These ﬁndings provide further insight into the
beneﬁcial vascular effects of PPAR c ligands in the prevention
and treatment of cardiovascular diseases.
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